Updated:
FMB Research
FMB Research, founded by Franklin M. Berger in New York, is an investment company with an early-stage focus on biotech. Lean structure, no public AUM.
FMB Research
FMB Research is a US-based investment company headquartered in New York. It focuses on a Venture Capital strategy.
General information
Firm type
Generalist Asset Manager
Location
Region
North America
Country
United States
City
New York
Corporate office
600 Lexington Avenue, 30th Floor, New York, NY 10022, United States
Principals
Franklin M. Berger
Managing Director and Founder
Sector focus
Frequently asked questions
Who runs investment decisions at FMB Research?
Franklin M. Berger is the sole named principal, serving as Managing Director and Founder. He holds the CFA designation and maintains a professional network in Connecticut and New York.
What sectors does FMB Research focus on?
Public record shows a concentration in early-stage biotechnology. Berger's relationship with Atea Pharmaceuticals — a clinical-stage antiviral company — and his role on the Brain Tumor Biotech Center Investment Advisory Board point to healthcare as the primary focus.
What is the size of FMB Research's investment portfolio?
No AUM or deployment figures are publicly disclosed. FMB Research does not publish financial statements, raise institutional capital, or report holdings, leaving portfolio scale unknown.
Where does FMB Research maintain offices?
The firm's headquarters are at 600 Lexington Avenue, 30th Floor, New York, NY. No additional office locations are disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: